Happy Nice Mall

It was a small trial, 18 rectal cancer patients, each taking the same drug.

But the results were surprising. Cancer disappeared in each patient undetected by physical examination, endoscopy, PET scans, or MRI scans.

From Memorial Sloan Kettering Cancer Center, Dr. Luis A. Diaz Jr. Paper Announcing the results, published Sunday in the New England Journal of Medicine and backed by pharmaceutical company GlaxoSmithKline, he said he doesn’t know of any other study in which a treatment completely eradicated cancer in every patient.

Dr. “I believe this is the first time in the history of cancer that this has happened,” Diaz said.

D., a colorectal cancer specialist at the University of California, San Francisco, who was not involved in the research. Alan P. Venook also said that he thinks this is a first.

A complete remission in every patient was “unheard of,” he said.

These rectal cancer patients faced challenging treatments such as chemotherapy, radiation, and possibly life-changing surgery that could result in bowel, urinary and sexual dysfunction. Some will need colostomy bags.

When the study was finished, they went in thinking they would have to go through these procedures because no one really expected their tumors to go away.

But they got a surprise: No further treatment was needed.

D., co-author of the paper presented Sunday at the annual meeting of the American Society of Clinical Oncology and oncologist at Memorial Sloan Kettering Cancer Center. “There were so many tears of happiness,” said Andrea Cercek.

Dr. Venook added that another surprise was that none of the patients had clinically significant complications.

On average, one in five patients has some type of adverse reaction to drugs that patients take, such as dostarlimab, known as checkpoint inhibitors. The drug was given every three weeks for six months and cost about $11,000 per dose. It unmasks cancer cells, allowing the immune system to identify and destroy them.

While most adverse reactions are easily managed, between 3 percent and 5 percent of patients taking checkpoint inhibitors have more serious complications, in some cases causing muscle weakness and difficulty swallowing and chewing.

No significant side effects, said Dr. “Either they didn’t treat enough patients, or somehow these cancers are completely different,” Venook says.

inside editorial Accompanying the article, University of North Carolina Lineberger Comprehensive Cancer Center, Dr. Hanna K. Sanoff, who was not involved in the research, described the article as “small but compelling.” Still, it’s not clear whether the patients were treated, she added.

In the editorial, Dr. “Little is known about the time it takes to find out if a clinically complete response to dostarlimaba equates to treatment,” Sanoff said.

A colorectal cancer specialist at Harvard Medical School, Dr. Kimmie Ng said that while the results were “remarkable” and “unprecedented,” they needed to be replicated.

Inspiration for rectal cancer study, Dr. A clinical trial conducted by Diaz in 2017 funded by drug maker Merck. It included 86 people with metastatic cancer originating from various parts of their bodies. But all of the cancers shared a gene mutation that prevented cells from repairing damage to DNA. These mutations occur in 4 percent of all cancer patients.

Patients in this trial received a Merck checkpoint inhibitor pembrolizumab for up to two years. In about one-third to one-half of patients, the tumors shrank or stabilized and they lived longer. Tumors disappeared in 10 percent of those who participated in the trial.

This is Dr. Cercek and Dr. It prompted Diaz to ask: What would happen if the drug was used much earlier in the course of the disease, before the cancer had a chance to spread?

They decided on a study of patients with locally advanced rectal cancer – tumors that have spread to the rectum and sometimes lymph nodes but not to other organs. Dr. Cercek noticed that chemotherapy did not help some of the patients with the same mutations that affected patients in the 2017 trial. During treatment, rectal tumors grew rather than shrinking.

Maybe Dr. Cercek and Dr. Diaz thought that immunotherapy with a checkpoint inhibitor would allow such patients to avoid chemotherapy, radiation, and surgery.

Dr. Diaz began asking companies that make checkpoint inhibitors if they would sponsor a small trial. They turned him down, saying the trial was too risky. He and Dr. They wanted to give the drug to patients who could recover with standard treatments, Cercek said. What the researchers suggest could allow cancers to grow beyond the point where they can be cured.

Dr. “It is very difficult to change the standard of care,” Diaz said. “All standard care machines want to do the surgery.”

Finally, Tesaro, a small biotech firm, agreed to sponsor the research. Tesaro was acquired by GlaxoSmithKline and Dr. Diaz said she needed to remind the larger company that they were doing the work—company executives had almost forgotten about trying the small.

Their first patient was Sascha Roth, 38. She first noticed some rectal bleeding in 2018, but other than that, she felt fine—she’s a runner and helps run a family furniture store in Bethesda, Md.

During a sigmoidoscopy, her gastroenterologist said, “Oh no. I wasn’t I’m waiting for this!”

The next day, the doctor called Ms. Roth. He had a tumor biopsy done. “It’s definitely cancer,” she told him.

“I completely melted,” he said.

He was scheduled to start chemotherapy soon at Georgetown University, but a friend first taught at Memorial Sloan Kettering, Dr. Philip insisted that he see Paty. Dr. Paty said she was almost certain her cancer contained the mutation that made it unlikely that she would respond well to chemotherapy. However, it turned out that Ms. Roth was eligible to enter clinical trial. If She had started chemotherapy, it wouldn’t have happened.

Not expecting a full response to dostarlimab, Ms. Roth planned to move to New York after the trial was over for radiation, chemotherapy and possibly surgery. To preserve fertility after anticipated radiation therapy her ovaries were removed and put back under her ribs.

After the trial, Dr. Cercek gave him the news.

“We looked at your scans,” he said. “Absolutely no cancer.” He did not need any other treatment.

“I told my parents,” said Mrs. Roth. “They didn’t believe me.”

But two years later, there is still no sign of cancer.